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Purpose: The aim of this study was to determine the force distribution and pattern 
of mastication after injection of botulinum toxin type A (BTX-A) into both masse-
ter muscles. The hypothesis to be tested was that the difference between right and 
left balance of occlusal force diminishes over time following BTX-A injection. 
Materials and Methods: Fifteen patients were submitted to BTX-A injection ther-
apy for subjective masseter hypertrophy. A total of 25 U of BTX-A (50 U in total) 
was injected into two points located 1 cm apart at the center of the lower one-third 
of both masseter muscles. All patients were examined using the T-Scan occlusion 
analysis system before and 4, 8, 12, and 24 weeks after BTX-A injection. Results: 
A significant change in force balance was found between the right and left sides 
over time and the difference between the two sides decreased with the time post-
injection, reaching a minimum at 12 weeks. Comparison of the force balance be-
tween the anterior and posterior occlusions revealed no significant difference at 
any of the time points. The occlusion and disclusion times (right and left sides) did 
not differ significantly with time since BTX-A injection. Conclusion: A decline in 
the difference in the clenching force between the left and right sides was found 
with increasing time up to 12 weeks following BTX-A injection.
Key Words:   Botulinum toxin type A, bite force, dental occlusion, masseter mus-
cle, mastication, time factors
INTRODUCTION
The clinical use of botulinum toxin type A (BTX-A) has expanded into the field of 
dentistry over the past decade. It is used in the treatment of masticatory and facial 
muscle spasm, severe bruxism, facial tics, orofacial dyskinesias, dystonias, and id-
iopathic hypertrophy of the masticatory muscles,1 as well as in the treatment of 
temporomandibular disorders,2 myofascial pain syndrome,3 headaches such as 
chronic migraine,4 recurrent dislocation of the temporomandibular joint (TMJ), 
drooling, and Frey’s syndrome.5 Application of BTX-A to various orofacial re-
gions in patients often requires injection into masticatory muscles such as the mas-
seter and temporalis muscles, which can cause temporary muscle paralysis, weak-
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Only subjects with normal occlusion conditions (class I) 
were included. Those with abnormal occlusion conditions 
that could affect the normal occlusion (e.g., missing teeth or 
severe tooth attrition) were excluded. Also those who had 
undergone dental treatment, temporomandibular disorder 
including TMJ osteoarthritis, and occlusal interference dur-
ing eccentric movement were excluded because it could 
also disturb the normal occlusion. Additionally, those who 
were pregnant or had injection of BTX-A during the previ-
ous 6 months were excluded because those condition could 
affect the results of the study.
BTX-A injection
The BTX-A used in this study was Botox (Allergan, Irvine, 
CA, USA); 100 U of Botox, obtained as a freeze-dried 
powder, was reconstituted to a concentration of 5 U/0.1 mL 
using 2 mL of 0.9% sterile, nonpreserved saline, and used 
immediately after reconstitution. A total of 25 units of 
BTX-A was injected into both masseter muscle bilaterally 
using a 1-mL syringe with a 29-gauge, 1/2-inch-long nee-
dle. Areas of masseter prominence on clenching were 
marked, and injected at two points at the center of the lower 
one-third of the masseter muscle separated by 1 cm (Fig. 
1). This site was chosen to avoid accidental toxin injection 
into the parotid gland, parotid duct, or facial artery.11 The 
injection was conducted by a single person in order to re-
duce error range. 
T-Scan analysis
All patients were examined using the T-Scan occlusion 
analysis system (T-Scan III, Yours Dental, Seoul, Korea) 
before and 4, 8, 12, and 24 weeks after BTX-A injection. 
This T-Scan system comprises Microsoft-Windows-based 
software, the associated hardware, and patented paper-thin 
disposable sensors.10 The information provided on T-Scan 
movies is listed in Table 1.
The sensor associated with the T-Scan system consists of 
two layers of Mylar (reinforced polyester film) in the form 
of a laminated pressure-sensitive ink grid. The film is cov-
ered by a silver-thread grid, the intersection points of which 
are bathed in conductive ink. When a patient closes firmly 
on the sensor, the resultant reduction in electric resistance is 
converted to 8-bit digital values and translated into an im-
age on the screen.12
The patient was seated in an upright position with be-
cause the supine position can alter the contact position.13 
The T-Scan III sensor and sensor support assembly were in-
ness, and atrophy.
The control of mastication is dependent in large part 
upon sensory feedback, which involves epithelial mechano-
receptors, periodontal, TMJ, and muscle afferents.6 Chang-
es in the afferent input from a muscle caused by injection of 
BTX-A can modify the response of the cortex and the mo-
tor neuron activity, and even initiate the activity of irrele-
vant muscles. Such injections into masticatory muscles can 
subsequently influence mastication directly by inducing 
muscle weakness and atrophy, as well as indirectly by influ-
encing the central pattern generator in the brainstem via 
modification of the sensory feedback from the masticatory 
muscle spindle.7
It has been often observed that BTX-A has analgesic ef-
fects and reduces hyperactivity in the injected muscle.8 How-
ever, in our clinic, some patients with pretreatment unilater-
al chewing habits report an equalization of masticatory 
force after BTX-A injection. This effect of BTX-A has yet 
to be studied in detail.
The T-Scan occlusion analysis system is a dental tool that 
is used to analyze masticatory force. It was first devised in 
1984 to measure occlusal forces and contact times as a 
prosthodontic adjunct in the treatment of occlusal problems 
and temporomandibular disorders. It has also been used as 
a measurement guide during prosthetic insertion and occlu-
sal adjustment procedures. Data on occlusal forces and con-
tact times are gathered by a recording sensor in the T-Scan 
system,9 and can subsequently be visualized in movie for-
mat, providing definitive diagnostic imaging of the force 
balance and function of the masticatory muscles.10
The aim of this study was to determine the force distribu-
tion and pattern of mastication after injection of BTX-A 
into the bilateral masseter muscles. The hypothesis to be 
tested was that the difference between right and left balance 
of occlusal force diminishes over time following BTX-A 
injection. 
MATERIALS AND METHODS
　　　
Patient selection
This study was approved by the Institutional Review Board 
committee of Yonsei School of Dentistry (No. 2-2011-0024). 
Twenty-four patients volunteered for this study and fifteen 
patients were selected during the screening process. These 
patients had BTX-A injection therapy for subjective masse-
ter hypertrophy, and T-Scan examination for this study. 
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dows statistics program (version 9.2, SAS Institute, Cary, 
NC, USA).
 
serted intraorally and positioned correctly. The T-Scan force-
movie mode was then activated manually by pushing the 
button on the handle. The patients were instructed to bite in 
the habitual intercuspal position, and then to make excur-
sive movements (not guided by the investigator). The right 
and left excursions were recorded separately. The patients 
were allowed a few minutes of rest between recordings. All 
of these procedures were repeated three times; the first two 
recordings were performed to familiarize the patient with 
the procedure, and the third record, made when the patient 
was completely familiar with the protocol, was used for the 
data analysis.
This study measured the distribution of forces between 
the left and right sides and between the anterior and posteri-
or regions during clenching, and the change in occlusion 
and disclusion times after BTX-A injection (Figs. 2 and 3). 
The disclusion time, in seconds, is required to disclude the 
working and nonworking molar interferences and non-
working premolar interferences from the habitual centric 
closure position to the completion of a mandibular excur-
sion, and the occlusion time is the time in seconds, from the 
first contact of the teeth to the maximal intercuspation.14
 
Statistical analysis
Linear mixed modeling for longitudinal data was conduct-
ed to analyze the change in the measured parameters over 
time. The interaction between times and groups was evalu-
ated by compound symmetry covariance structure, banded 
Toeplitz, or autoregressive covariance structure. Bonferro-
ni’s correction was used for post-hoc analysis. A p value of 
<0.01 was considered indicative of statistical significance. 
All statistical analyses were performed using the SAS Win- Fig. 1. The red boxed area shows the botulinum toxin type A injection site. 
Table 1. The Information Provided on T-Scan Movies
The distribution of forces (as percentages) around the arch
The timing of the forces-early or late
The presence of interference during closure
The balance of forces left to right and/or anterior to posterior 
  at any point during closure
The effectiveness of guidance patterns that provide 
  somatosensory muscle control
Evidence of muscle balance or imbalance during function
Evidence of abnormal dental forces secondary to injury, 
  pain, or inflammation
Presence and timing of forces that are above or below the 
  average for this patient
Fig. 2. Balance of clenching force in a T-Scan movie (A: divided into two parts: left and right sides, B: divided into four parts labeled in 
clockwise direction: anterior left, anterior right, posterior right, posterior left). 
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Fig. 3. (A) Occlusion time. (B) Disclusion time. (A) A1 is the point the teeth start to occlude, B1 is the point the dentition is fully occluded, 
and the difference of A1 and B1 is occlusion time, marked as OT. (B) C1 is the point lateral movement starts, D1 is the point the dentition is 
fully separated and the difference is disclusion time, marked as DT. OT, occlusion time; DT, disclusion time.
Fig. 4. Force distribution on right and left sides before BTX-A injection (A) and 12 weeks thereafter (B). (A) In the left figure, before botuli-
num toxin injection the distribution of the left and right force was uneven, 72.1% and 27.9%. 12 weeks post injection, (B) the right figure, 
the distribution evened as left 58.1% and right 27.9%. BTX-A, botulinum toxin type A.
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condition that can occur unilaterally or bilaterally. Unilater-
al or bilateral hypertrophy of the masseter muscle is charac-
terized by an increase in the volume of the muscle mass. 
This condition is benign, asymptomatic, and must be differ-
entiated from parotid gland disease odontogenic problems, 
and rare neoplasms of muscular tissue. The reasons why 
patients request a medical consultation are predominantly 
related to aesthetics, especially if the hypertrophy is unilat-
eral due to a noticeable asymmetry of the lower third of the 
face.16,17 This study was intended for patients who com-
plained only about masseter hypertrophy, and not other 
symptoms. 
Botulinum toxin is a potent biological toxin produced by 
the Gram-positive bacterium Clostridium botulinum.18 It is 
a presynaptic neurotoxin that causes dose-dependent weak-
ness or paralysis in skeletal muscles by blocking the calci-
um-mediated release of acetylcholine from motor nerve 
endings.19,20 BTX-A, one of seven subtypes of the toxin, is 
a dichain protein consisting of a 50-kD light chain linked to 
a 100-kD heavy chain by a disulfide bond; it functionally 
denervates the affected portions of the muscle and it pri-
marily affects α-motor neuron function, but it may also affect 
the γ motor neurons in the muscle spindles.21 Local paralysis 
is reversed chiefly by neural sprouting, effectively reinnervat-
ing the muscle.22 Long-term reductions in α, γ, and Ia neuro-
nal activity may have indirect effects on the central nervous 
system. This was demonstrated when Moreno-López, et al.23 
who showed that single injections of BTX-A into the lateral 
rectus muscle of cats caused inhibition of abduction, altered 
electromyographic signals in the contralateral ocular mus-
cles, and a disruption of the abducens motor neuron dis-
charge patterns that lasted longer than 2 months. 
BTX-A may also act directly or indirectly on nociceptors 
that affect transmission of sensory signals through A-δ and 
RESULTS
 
Changes in the distribution of forces
A significant change in force balance was found between 
the right and left sides over time (i.e., preinjection and 4, 8, 
12, and 24 weeks post-BTX-A injection) and at each mea-
surement time point (p<0.0001). The difference between 
the two sides decreased with the time postinjection, reach-
ing a minimum at 12 weeks (Fig. 4). These findings reflect 
the well-established time course of the actions of BTX-A.15 
In other words, according to this result, the left and right 
clenching force becomes more balanced with the increasing 
effect of botulinum toxin injection. 
Comparison of the force balance between the anterior 
and posterior occlusions revealed no significant difference 
at any of the time points (i.e., preinjection and 4, 8, 12, and 
24 weeks postinjection; p>0.01 for all). Furthermore, com-
parison of the preinjection force balance with those mea-
sured at 4, 8, 12, and 24 weeks postinjection revealed no 
significant difference at any time point (p>0.05 for all) (Ta-
ble 2). In other words, there is no correlation between the 
balance of anterior and posterior masticatory force and the 
increasing effect of botulinum toxin injection.
Changes in occlusion and disclusion times
The occlusion and disclusion times (right and left sides) did 
not differ significantly with time after BTX-A injection (p> 
0.01) (Table 3). 
DISCUSSION
Benign masseter hypertrophy is a relatively uncommon 
Table 2. Changes in the Force Distribution (%; Mean±SD) after Injection of BTX-A (n=15)
Preinjection After 4 wks After 8 wks After 12 wks After 24 wks
Difference between left and right sides   25.5±10.1   15.7±10.3* 11.9±6.0*   7.1±5.6*     16.4±11.4*
Difference between anterior and posterior 91.0±7.5 90.7±10.1 88.2±12.8 87.6±10.5 87.8±8.7
BTX-A, botulinum toxin type A.
*p<0.01 (compared to preinjection).
Table 3. Change in Occlusion and Disclusion Times (in Seconds) with Time after BTX-A Injection (n=15)
Preinjection After 4 wks After 8 wks After 12 wks After 24 wks
Occlusion time 0.32±0.26 0.39±0.51 0.22±0.11 0.20±0.10 0.25±0.10
Disclusion time (right) 1.52±1.32 2.54±2.17 2.01±1.82 2.69±2.35 1.82±1.79
Disclusion time (left) 1.30±1.53 1.66±1.94 2.63±2.24 3.24±2.38 3.05±2.30
BTX-A, botulinum toxin type A.
*p<0.01 (compared to preinjection).
Ji Hee Song, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 4   July 20141128
values, were therefore analyzed since it was felt that the 
data obtained at the first and second recordings would be 
inaccurate. Second, since there was no control group, it was 
not possible to determine whether there was a placebo ef-
fect. Future studies should address these limitations.
In conclusion, fifteen patients were examined using the 
T-Scan system before and after BTX-A injection into the 
masseter muscles. A decline in the difference in the clench-
ing force between the left and right sides was found with 
increasing time (and hence increasing medicinal effect) up 
to 12 weeks following BTX-A injection.
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